期刊文献+

类风湿关节炎血清白细胞介素17和肿瘤坏死因子α及滑膜病变检测的意义 被引量:2

Detection of interleukin-17 and tumor necrosis factor-alpha and synovium pathological changes in patients with rheumatoid arthritis and significance
原文传递
导出
摘要 目的探讨血清白细胞介素17(IL-17)和肿瘤坏死因子仪(TNF-α)及滑膜病变检测在类风湿关节炎(RA)患者中的临床意义。方法应用酶联免疫吸附测定法(EuSA)对50例活动期RA患者(活动期RA组)、50例稳定期RA患者(稳定期RA组)和50例体检健康者(健康对照组)血清IL-17和TNF-α水平进行检测,同时取其关节滑膜进行病理检查。结果活动期RA组血清IL-17和TNF-α水平[(42.60±11.30)、(113.20±13.11)mg/L]明显高于稳定期RA组[(19.60±5.75)、(14.50±5.33)mg/L]和健康对照组[(7.40±3.32)、(10.90±2.24)mg/L](P〈0.01);稳定期RA组血清IL-17水平高于健康对照组(P〈0.05),而TNF-α水平与健康对照组比较差异无统计学意义(P〉0.05)。RA患者的滑膜与健康对照组相比呈明显的病态。结论RA患者血清IL-17和TNF-α水平及滑膜病变的变化特点与病情有关,联合动态监测有助于临床观察和治疗。 Objective To investigate the levels of serum interleukin -17(IL-17) and tumor necrosis factor -alpha(TNF-α) and synovium pathological changes in patients with rheumatoid arthritis (RA) and its clinical significance. Methods The levels of serum IL-17 and TNF-α in 50 patients with active phase of RA (active phase of RA group) ,50 patients with stable phase of RA (stable phase of RA group) and 50 normal controls (NC group ) were measured by enzyme-linked immunospecific assay(ELISA ), and the synovium was detected by pathological examination. Results The levels of serum IL-17 and TNF-α in active phase of RA group [ (42.60 ± 11.30), ( 113.20 ± 13.11 ) mg/L ] were significantly higher than those in stable phase of RA group [ ( 19.60 ± 5.75), ( 14.50 ±5.33 ) mg/L] and NC group [ (7.40 ± 3.32), ( 10.90 ± 2.24) mg/L] (P 〈 0.01 ), the level of serum IL-17 in stable phase of RA group was significantly higher than that in NC group (P 〈 0.05), but the level of TNF-α had no significant difference between stable phase of RA group and NC group (P 〉 0.05 ). The synovium was significantly different between RA patients and NC group. Conclusion IL-17 and TNF-α are more sensitive index for detecting the activity of RA and may play important roles in monitoring the therapeutic effects and prognosis of RA.
作者 张雯丽 李慧
出处 《中国医师进修杂志》 2012年第2期14-16,共3页 Chinese Journal of Postgraduates of Medicine
关键词 关节炎 类风湿 白细胞介素17 肿瘤坏死因子Α 滑膜病变 Arthritis, rheumatoid Interleukin-17 Tumor necrosis factor-alpha Synovium pathological changes
  • 相关文献

参考文献9

二级参考文献74

共引文献91

同被引文献24

  • 1FiresteinGS,BuddRC,HarrisEDJr,et al.凯利风湿病学[M].栗占国,唐福林,译.8版.北京:北京大学医学出版社,2011:1573-1574,1578.
  • 2Yoshiya, Tanaka.New trends in therapy for arthritis rheumatoid[J]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, 95 ( 3 ) : 505-509.
  • 3Cohen P A, Job D C H, Lalande G, et al. Overview of the radiology of juvenile idiopathic arthritis ( JIA ) [J].European Journal of Radiology, 2000, 33 (2) : 94-101.
  • 4Prevoo ML, van' t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis[J]. Arthritis Rheum, 1995, 38(1): 44-48. DOI: lO.1002/art. 1780380107.
  • 5Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis[J]. Arthritis Rheum, 1995, 38(6): 727-735. DOI: 10. lO02/art. 1780380602.
  • 6Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis[J]. Arthritis Rheum, 1995, 38(6): 727-735. DOI: 10.1002/art.1780380602.
  • 7Du F, Lii LJ, Fu Q, et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen- induced arthritis[J]. Arthritis Res Ther, 2008, 10(6): R136. DOI: 10.1186/ar2554.
  • 8Aikawa Y, Tanuma N, Shin T, et al. A new anti-rheumatic drug, T- 614, effectively suppresses the development of autoimmune encephalomyelitis[J]. J Neuroimmunol, 1998, 89(1/2): 35-42.
  • 9Tanaka K, Yamamoto T, Aikawa Y, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immnnoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice[J]. Rheumatology (Oxford), 2003, 42(11): 1365-1371.
  • 10Kuriyama K, Higuchi C, Tanaka K, et al. A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo[J]. Biochem Biophys Res Commun, 2002, 299(5): 903-909. DOI: 10.1016/S0006-291 X(02)02754-7.

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部